Oct 07, 2025 • Benzinga
SOMEWHAT-BULLISH
Tony Robbins Joins Minnect as Strategic Investor and Expert on the Platform
FT. LAUDERDALE, Fla., Oct. 7, 2025 /PRNewswire/ -- Minnect, the premier platform connecting people with world-class experts, continues to expand its mission of delivering access to leaders who can transform lives and businesses announcing today that Tony Robbins has joined as both a strategic ...
Oct 07, 2025 • Cointelegraph
NEUTRAL
5 Crypto Scams Every Investor Should Watch Out for in 2025
From fake support to deepfake fraud, several crypto scams demand your attention in 2025. These are the ones you simply can't afford to ignore.
Oct 07, 2025 • Benzinga
NEUTRAL
Pentagon Revises Controversial Press Rules After Backlash: Report - Comcast ( NASDAQ:CMCSA ) , Walt Disney ( NYSE:DIS )
In response to criticism from national news organizations, the Department of War has reportedly revised its new press access restrictions. The Pentagon announced on Monday that it has made changes to the new rules for journalists seeking access to the department.
Oct 07, 2025 • Benzinga
SOMEWHAT-BULLISH
TAG to Honor Gloria Reuben, Dr. Jeanne Marrazzo, and Richard Lynn at the 2025 Research in Action Awards
NEW YORK, Oct. 7, 2025 /PRNewswire/ -- TAG's annual Research in Action Awards is our most anticipated night of the year. We'll gather with our supporters and community members on Monday, October 20, at the beautiful Angel Orensanz Foundation in New York City, in what's expected to be a memorable ...
Oct 07, 2025 • Benzinga
SOMEWHAT-BULLISH
Paramount Buys The Free Press, Names Its Co-Founder As CBS News' Editor-In-Chief - Paramount Skydance ( NASDAQ:PSKY )
Media company Paramount Skydance ( NASDAQ:PSKY ) has named Bari Weiss as the editor-in-chief of CBS News as part of a deal to acquire the online news site she founded, The Free Press.
Oct 07, 2025 • South China Morning Post
SOMEWHAT-BULLISH
China's pharmaceutical sector surges amid growth in sales, licensing income
The Chinese pharmaceutical sector has significantly outperformed the broader market this year, driven by strong sales growth and a rapid increase in income from licensing drugs to international partners, according to HSBC.